<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05001074</url>
  </required_header>
  <id_info>
    <org_study_id>202000134</org_study_id>
    <nct_id>NCT05001074</nct_id>
  </id_info>
  <brief_title>Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients</brief_title>
  <acronym>REVOLUTION</acronym>
  <official_title>Randomized Controlled Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heleen Grootjans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung transplantation is a life-saving option in patients with end-stage lung disease. The&#xD;
      introduction of calcineurin inhibitors has significantly improved long-term outcome in lung&#xD;
      transplantation. The most frequently used calcineurin inhibitor as maintenance therapy is&#xD;
      immediate release tacrolimus, dosed twice daily, which has shown to reduce both acute and&#xD;
      chronic rejection. However, a drawback to the administration of tacrolimus is its toxicity.&#xD;
      Especially progressive renal toxicity, new onset diabetes and hypertension contribute to the&#xD;
      high cardiovascular burdon in this patient group. Since a few years an once daily extended&#xD;
      release tacrolimus has been introduced in solid organ transplantation. The advantage of&#xD;
      extended release tacrolimus is its prolonged release and higher bioavailability than other&#xD;
      tacrolimus formulations. This result in lower peaks, more stable serum levels over 24 hours,&#xD;
      and less fluctuation of blood concentrations.&#xD;
&#xD;
      Long-term toxicity outcome of extended release tacrolimus after lung transplantation has not&#xD;
      been studied so far. Therefore the potential benefit of exteded release tacrolimus in de novo&#xD;
      and stable post-lung transplant recipients should be investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung transplantation is a life-saving option in patients with end-stage lung disease. The&#xD;
      introduction of calcineurin inhibitors (CNI) has significantly improved long-term outcome in&#xD;
      lung transplantation. The most frequently used CNI as maintenance therapy is immediate&#xD;
      release tacrolimus, dosed twice daily, which has shown to reduce both acute and chronic&#xD;
      rejection. However, a drawback to the administration of tacrolimus is its toxicity.&#xD;
      Especially progressive renal toxicity, new onset diabetes and hypertension contribute to the&#xD;
      high cardiovascular burdon in this patient group. In lung transplant recipients the incidence&#xD;
      of severe renal impairment, new onset of diabetes mellitus, hypertension and dyslipidemia is&#xD;
      53,9%, 40%, 80% and 40,3% post lung transplantation. Tremor is one of the most common CNI&#xD;
      induced neurological toxic effect, besides polyneuropathy, headaches, insomnia, vertigo,&#xD;
      dysesthesia and reduced cognitive ability. These complications are, among others, attributed&#xD;
      to high peak serum tacrolimuslevels, whereas the effectiveness of the drug is determined by&#xD;
      the area under the curve. In general lung transplant recipients have higher peak and trough&#xD;
      levels when compared to other solid organ transplant recipients and therefore potentially&#xD;
      experience more severe toxic side effects.&#xD;
&#xD;
      Since a few years an once daily extended release tacrolimus has been introduced in solid&#xD;
      organ transplantation. The advantage of extended release tacrolimus is its prolonged release&#xD;
      and higher bioavailability than other tacrolimus formulations. This result in lower peaks,&#xD;
      more stable serum levels over 24 hours, and less fluctuation of blood concentrations. In&#xD;
      addition, for an equal overall systemic tacrolimus exposure a 30% lower dosage is needed for&#xD;
      extended release tacrolimus when compared to other formulations. In kidney and liver&#xD;
      transplantation, extended release tacrolimus is safe and effective. Langone et al&#xD;
      demonstrated in an enriched population of kidney transplant patients with tremor, that&#xD;
      extended release tacrolimus improved hand tremor compared to immediate release tacrolimus.&#xD;
&#xD;
      Long-term toxicity outcome of extended release tacrolimus after lung transplantation has not&#xD;
      been studied so far. Therefore the potential benefit of exteded release tacrolimus in de novo&#xD;
      and stable post-lung transplant recipients should be investigated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>De novo cohort, 2 arms: de novo lung transplant recipients. Conversion cohort, 2 arms: stable lung transplant recipients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>renal function: absolute change in eGFR</measure>
    <time_frame>2 years</time_frame>
    <description>absolute change in eGFR absolute change in eGFR change in eGFR at 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>graft function</measure>
    <time_frame>2 years</time_frame>
    <description>Acute graft dysfunction is a clinical diagnoses, with or without histological confirmation, and indictation for rejection treatment such as methylprednisolon. Chronic graft dysfunction is defined according to the ISHLT guidelines, as a persistent decline (≥20%) in measured FEV1 value from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function: 40% eGFR reduction</measure>
    <time_frame>2 years</time_frame>
    <description>40% eGFR reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function: 50% eGFR reduction</measure>
    <time_frame>2 years</time_frame>
    <description>50% eGFR reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function:end stage kidney disease</measure>
    <time_frame>2 years</time_frame>
    <description>end stage kidney disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypertension</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of inadequate regulated or new onset of hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diabetes mellitus</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of inadequate glycemic control of preexisting diabetes mellitus or new onset diabetes after transplantation (NODAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malignancies</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurological function: tremor</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of or change in pre-existing hand tremor by using the validated Fahn-Tolosa-Martin (FTM) tremor rating scale (grades of tremor 0-4, in which 0 indicated no tremor and 4 severe tremor)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurological function: polyneuropathy</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of or change in pre-existing polyneuropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurological function: sleep quality</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of or change in sleep quality by using validated questionnaire: Pittsburg Sleep Quality Index (PSQI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurological function: cognitive functioning</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of or change in cognitive functioning by using validated questionnaire: the Cognitive Functioning Questionnaire (CFQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life score</measure>
    <time_frame>2 years</time_frame>
    <description>change in SF36 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacogenetic</measure>
    <time_frame>2 years</time_frame>
    <description>explorative endpoints: effects of well known variances in CYP3A4, CYP3A5 and ABCB1 transporter function on tacrolimus metabolism (resulting in so-called slow and fast tacrolimus metabolisers) on long-term tacrolimus renal toxicity by using absolute eGFR change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacogenetic</measure>
    <time_frame>2 years</time_frame>
    <description>explorative endpoints: effects of well known variances in CYP3A4, CYP3A5 and ABCB1 transporter function on tacrolimus metabolism (resulting in so-called slow and fast tacrolimus metabolisers) on long-term tacrolimus neurological toxicity: change in incidence of or change in pre-existing hand tremor by using the validated Fahn-Tolosa-Martin tremor rating scale</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Lung Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>de novo cohort, extended release tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>de novo cohort, extended release tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>de novo cohort, immediate release tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>de novo cohort, immediate release tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conversion cohort, extended release tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>conversion cohort, extended release tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conversion cohort, immediate release tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conversion cohort, immediate release tacrolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extended release tacrolimus</intervention_name>
    <description>de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when &gt;1 year post-lungtransplantation and with stable graft function</description>
    <arm_group_label>conversion cohort, extended release tacrolimus</arm_group_label>
    <arm_group_label>de novo cohort, extended release tacrolimus</arm_group_label>
    <other_name>LCP tacrolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate release tacrolimus</intervention_name>
    <description>de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when &gt;1 year post-lungtransplantation and with stable graft function</description>
    <arm_group_label>conversion cohort, immediate release tacrolimus</arm_group_label>
    <arm_group_label>de novo cohort, immediate release tacrolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Single or bilateral lung transplantation&#xD;
&#xD;
          -  On twice daily tacrolimus with stable trough levels in target range&#xD;
&#xD;
          -  Participant in the TransplantLines biobank study in the UMCG&#xD;
&#xD;
        Additional criteria for Conversion cohort:&#xD;
&#xD;
          -  At least one year after lung transplantation with a stable clinical course and lung&#xD;
             function&#xD;
&#xD;
          -  eGFR &gt;30ml/min*1.73m2 calculated with the CKD-EPI formula&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Administration of mTOR inhibitors; everolimus, sirolimus&#xD;
&#xD;
          -  Quadruple immunosuppression&#xD;
&#xD;
          -  Renal transplantation&#xD;
&#xD;
          -  The subject has any disease or condition that might interfere with completion of this&#xD;
             study or reaching the primary endpoint (e.g., life expectancy of &lt;3 years, renal&#xD;
             replacement therapy at start study)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tji Gan</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heleen Grootjans</last_name>
    <phone>0031503616161</phone>
    <email>h.grootjans@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tji Gan</last_name>
    <phone>0031503616161</phone>
    <email>c.t.gan@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University medical center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heleen Grootjans</last_name>
      <phone>0031503616161</phone>
    </contact>
    <investigator>
      <last_name>Tji Gan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heleen Grootjans</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erik Verschuuren</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Berger</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daan Touw</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Sintes H, Sáez-Giménez B, Berastegui C, López-Meseguer M, Monforte V, Bravo C, Vima J, Gómez-Ollés S, Roman A. Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients. Transplantation. 2018 Oct;102(10):e439-e446. doi: 10.1097/TP.0000000000002348.</citation>
    <PMID>29965950</PMID>
  </results_reference>
  <results_reference>
    <citation>Méndez A, Berastegui C, López-Meseguer M, Monforte V, Bravo C, Blanco A, Camós S, Pou L, Roman A. Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation. Transplantation. 2014 Feb 15;97(3):358-62. doi: 10.1097/01.TP.0000435699.69266.66.</citation>
    <PMID>24492423</PMID>
  </results_reference>
  <results_reference>
    <citation>TruneČka P, Klempnauer J, Bechstein WO, Pirenne J, Friman S, Zhao A, Isoniemi H, Rostaing L, Settmacher U, Mönch C, Brown M, Undre N, Tisone G; DIAMOND† study group. Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged-Release Tacrolimus Regimens-The DIAMOND Study. Am J Transplant. 2015 Jul;15(7):1843-54. doi: 10.1111/ajt.13182. Epub 2015 Feb 23.</citation>
    <PMID>25707487</PMID>
  </results_reference>
  <results_reference>
    <citation>Sánchez Fructuoso A, Ruiz JC, Franco A, Diekmann F, Redondo D, Calviño J, Serra N, Aladrén MJ, Cigarrán S, Manonelles A, Ramos A, Gómez G, González Posada JM, Andrés A, Beneyto I, Muñiz AL, Perelló M, Lauzurica R. Effectiveness and safety of the conversion to MeltDose(®) extended-release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: A retrospective study. Clin Transplant. 2020 Jan;34(1):e13767. doi: 10.1111/ctr.13767. Epub 2019 Dec 31.</citation>
    <PMID>31815310</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Heleen Grootjans</investigator_full_name>
    <investigator_title>Drs. Heleen Grootjans, internist-nephrologist</investigator_title>
  </responsible_party>
  <keyword>lung transplantation</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>extended release tacrolimus</keyword>
  <keyword>LCP tacrolimus</keyword>
  <keyword>immediate release tacrolimus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

